Vicarious Surgical has submitted an application to list its Class A common stock on the Nasdaq, the company announced today.
The Massachusetts-based surgical robot developer said the move is a part of a broader strategy to strengthen its capital markets profile.
“These actions position us with a more capital-efficient operating model while we continue advancing toward system design freeze by year-end,” said Vicarious Surgical CEO Stephen From. “At the same time, we are actively pursuing a path back to a national exchange through our Nasdaq listing application. We believe these steps strengthen our foundation and support our long-term objective of bringing our robotic surgical platform to market.”
Vicarious also filed a preliminary proxy statement with the Securities and Exchange Commission (SEC) seeking stockholder approval to authorize its board of directors to implement a reverse stock split of its common stock at a rate to be determined by the board, the news release said. The reverse stock split is intended to assist Vicarious’ shares to meet Nasdaq’s minimum bid price requirement for listing.
The announcement comes after the NYSE suspended Vicarious’ stock and initiated the delisting process. Vicarious began trading on the OTCID market tier soon after, and today the company said it’s submitted an application to upgrade its quotation to the OTCQB Venture Market.
Vicarious believes that trading on the OTCQB Venture Market will enchanted trading liquidity as it pursues a potential Nasdaq listing.
Over the past several months, the company has implemented operational and cost discipline initiatives to streamline operating structure and reduce cash burn without disrupting its development timeline. The robotics company said an increased use of outsourcing and operational efficiencies has contributed to significant structural improvement.
As a result, Vicarious reduced its expected 2026 cash burn guidance from $35 million to approximately $19 million. In mid-2025, Vicarious’ annual cash burn was approximately $50 million, which the company attributed to its previous operating structure.
Vicarious said its cost discipline strategy has not slowed development of the Vicarious Surgical System, which remains on track to achieve system design freeze by the end of 2026.
With the current operating plan, the company believes its existing cash resources “provide runway” through the second quarter of 2026 and support its capital markets strategy pursuits.
